Maze Therapeutics, a clinical-stage biopharmaceutical company, announced that CEO Jason Coloma will participate in three upcoming investor conferences between November and December 2026. These include the Guggenheim Healthcare Innovation Conference, Jefferies Global Healthcare Conference in London, and Evercore Healthcare Conference. The presentations will highlight the company's progress in developing precision medicines for kidney and metabolic diseases, including their Phase 2 programs MZE829 and MZE782. Live webcasts will be available on Maze Therapeutics' website for 60 days after the events.
Maze Therapeutics news is provided with Pluang's Health sector market data for context. Of 150 priced US Health stocks on Pluang, 74 rose and 69 fell today. Notable movers include NUVB at USD 4.81 (+4.79%), ACB at USD 4.40 (+4.27%), and TVTX at USD 47.30 (-3.98%). Data is as of Nov 03, 2026 19:02 WIB.
Anavex Life Sciences appointed Terrie Kellmeyer, Ph.D., as President and CEO, also joining the Board. Kellmeyer, with over 30 years in biopharma, has led the company through key clinical milestones including FDA clearance for Fragile X syndrome trial...
Cardiff Oncology, a clinical-stage biotech company focusing on cancer therapies via PLK1 inhibition, announced it will present at the UBS Global Biopharma Conference on November 16-17, 2026. The company's CEO, Mani Mohindru, will deliver a fireside c...
Seyond Inc is enhancing its smart city solutions by integrating advanced LiDAR 3D sensing with AI-powered analytics and collaborations with Dell Technologies, NVIDIA, and AMSYS. This expansion supports improved safety, transportation, and infrastruct...
Stella-Jones Inc. announced a teleconference on November 4, 2026, at 10:00 AM EST to discuss its third-quarter 2026 financial results. The event is open to investors, analysts, and interested parties, with live streaming and phone access provided. A ...
Stella-Jones Inc. announced a conference call for November 4, 2026, at 10:00 AM EST to discuss its third quarter 2026 financial results. The call is open to investors, analysts, and interested parties and will be webcast live with a recording availab...
